Details for New Drug Application (NDA): 203277
✉ Email this page to a colleague
The generic ingredient in LAMIVUDINE is lamivudine; nevirapine; zidovudine. There are twenty-nine drug master file entries for this compound. Additional details are available on the lamivudine; nevirapine; zidovudine profile page.
Summary for 203277
Tradename: | LAMIVUDINE |
Applicant: | Hetero Labs Ltd V |
Ingredient: | lamivudine |
Patents: | 0 |
Pharmacology for NDA: 203277
Mechanism of Action | Nucleoside Reverse Transcriptase Inhibitors |
Medical Subject Heading (MeSH) Categories for 203277
Suppliers and Packaging for NDA: 203277
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
LAMIVUDINE | lamivudine | TABLET;ORAL | 203277 | ANDA | Camber Pharmaceuticals, Inc. | 31722-753 | 31722-753-06 | 600 TABLET, FILM COATED in 1 BOTTLE (31722-753-06) |
LAMIVUDINE | lamivudine | TABLET;ORAL | 203277 | ANDA | Camber Pharmaceuticals, Inc. | 31722-753 | 31722-753-31 | 10 TABLET, FILM COATED in 1 BLISTER PACK (31722-753-31) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 150MG | ||||
Approval Date: | Jan 6, 2014 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | 300MG | ||||
Approval Date: | Jan 6, 2014 | TE: | AB | RLD: | No |
Complete Access Available with Subscription